Goltor

Goltor is a prescription oral medication that combines the active ingredients simvastatin and ezetimibe. It is formulated to target cholesterol metabolism, though specific strength and dosage form are not disclosed. Marketed in the European Union, Goltor belongs to the statin and cholesterol absorption inhibitor classes and is used under medical supervision for managing lipid disorders.

Goltor is indicated for the treatment of various lipid disorders where lowering low‑density lipoprotein (LDL) cholesterol is required. It is commonly prescribed as part of a comprehensive lipid‑lowering strategy that includes diet and lifestyle changes.

- Primary hypercholesterolemia, especially when statin monotherapy is insufficient. - Mixed dyslipidemia with elevated LDL‑C and triglycerides. - Familial hypercholesterolemia in adults. - Patients who require additional LDL‑C reduction beyond that achieved with a statin alone. - Adjunct therapy in individuals with high cardiovascular risk profiles.

Goltor may cause a range of side effects, most of which are mild and transient. Serious adverse events are less common but require prompt medical attention.

Common: - Muscle aches or weakness (myalgia). - Headache. - Abdominal discomfort or dyspepsia. - Elevated liver enzymes. - Diarrhea. - Fatigue.

Serious: - Rhabdomyolysis or severe muscle breakdown. - Acute liver injury or hepatitis. - Severe allergic reactions (e.g., angioedema, anaphylaxis). - Persistent elevation of creatine kinase. - Acute pancreatitis (rare).

Before initiating Goltor, clinicians should evaluate patient history and laboratory values to minimize risk. Specific considerations include:

- Contraindicated in pregnancy; women of childbearing potential must use effective contraception. - Assess baseline liver function tests; avoid use in active liver disease. - Monitor creatine kinase levels if patients report muscle symptoms. - Caution in patients with renal impairment; dose adjustment may be needed. - Review for potential drug interactions, especially with CYP3A4 inhibitors. - Advise patients to report unexplained muscle pain, dark urine, or jaundice promptly.

Goltor can interact with several medication classes, influencing its efficacy or safety profile.

Avoid: - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ritonavir) which can increase simvastatin exposure. - Fibrates (gemfibrozil) that raise the risk of myopathy. - Certain antacids containing aluminum or magnesium that may affect ezetimibe absorption. - Warfarin, as lipid‑lowering therapy may alter INR stability.

Use with caution: - Other statins or high‑intensity lipid‑lowering agents. - Niacin, which can increase the risk of hepatotoxicity. - Digoxin, due to potential alterations in plasma concentrations. - Antihypertensive agents, as blood pressure changes may be observed.